Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 9, 2014 - Issue 1
Submit an article Journal homepage
88
Views
1
CrossRef citations to date
0
Altmetric
Reviews

Sporadic primary hyperparathyroidism: medical and surgical updates

Zeina HabibMercy Hospital and Medical Center - Internal Medicine, Section of Endocrinology and Metabolism, 2525 S Michigan Ave, Chicago, IL 60616, USA
,
Adam KabakerLoyola University - Surgery, Section of Endocrine Surgery, 2160 S. First Avenue, Maywood, IL 60153, USA
&
Pauline CamachoLoyola University - Endocrinology and Metabolism, 2160 S. First Avenue, Maywood, IL 60153, USACorrespondence[email protected]
Pages 31-44 | Published online: 13 Dec 2013

References

  • Clarke BL. Epidemiology of primary hyperparathyroidism. J. Clin. Densitom. 16(1), 8–13 (2013).
  • Habib Z, Camacho P. Primary hyperparathyroidism. Exp. Rev. Endocrinol. Metab. 5(3), 375–387 (2010).
  • Yeh MW, Ituarte PH, Zhou HC et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J. Clin. Endocrinol. Metab. 98(3), 1122–1129 (2013).
  • Yu N, Donnan PT, Leese GP. A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clin. Endocrinol. (Oxf) 75(2), 169–176 (2011).
  • Yu N, Donnan PT, Flynn RW et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin. Endocrinol. (Oxf) 73(1), 30–34 (2010).
  • Habib Z, Camacho P. Primary hyperparathyroidism: an update. Curr. Opin. Endocrinol. Diabetes Obes. 17(6), 554–560 (2010).
  • Belardi V, Fiore E, Giustarini E et al. Is the risk of primary hyperparathyroidism increased in patients with untreated breast cancer? J. Endocrinol. Invest. 36(5), 321–325 (2013).
  • Woll ML, Mazeh H, Anderson BM, Chen H, Sippel RS. Breast radiation correlates with side of parathyroid adenoma. World J. Surg. 36(3), 607–611 (2012).
  • Agarwal A, Gupta SK, Sukumar R. Hyperparathyroidism and malnutrition with severe vitamin D deficiency. World J. Surg. 33(11), 2303–2313 (2009).
  • Ludvigsson JF, Kampe O, Lebwohl B, Green PH, Silverberg SJ, Ekbom A. Primary hyperparathyroidism and celiac disease: a population-based cohort study. J. Clin. Endocrinol. Metab. 97(3), 897–904 (2012).
  • Paik JM, Curhan GC, Taylor EN. Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study. BMJ 345, e6390 (2012).
  • Ghosh S, Collier A, Clark D, Storey C, Malik I. Social deprivation and primary hyperparathyroidism. Endocr. Pract. 16(6), 982–985 (2010).
  • Macfarlane DP, Yu N, Donnan PT, Leese GP. Should ‘mild primary hyperparathyroidism’ be reclassified as ‘insidious’: is it time to reconsider? Clin. Endocrinol. (Oxf) 75(6), 730–737 (2011).
  • Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 96(8), 2377–2385 (2011).
  • Starup-Linde J, Waldhauer E, Rolighed L, Mosekilde L, Vestergaard P. Renal stones and calcifications in patients with primary hyperparathyroidism: associations with biochemical variables. Eur. J. Endocrinol. 166(6), 1093–1100 (2012).
  • Vezzoli G, Scillitani A, Corbetta S et al. Polymorphisms at the regulatory regions of the CASR gene influence stone risk in primary hyperparathyroidism. Eur. J. Endocrinol. 164(3), 421–427 (2011).
  • Sorensen MD, Duh QY, Grogan RH, Tran TC, Stoller ML. Differences in metabolic urinary abnormalities in stone forming and nonstone forming patients with primary hyperparathyroidism. Surgery 151(3), 477–483 (2012).
  • Spivacow FR, Negri AL, del Valle EE, Fradinger E, Martinez C, Polonsky A. Persistence of hypercalciuria after successful surgical treatment for primary hyperparathyroidism. Int. Urol. Nephrol. 44(3), 857–863 (2012).
  • Lewiecki EM, Miller PD. Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. J. Clin. Densitom. 16(1), 28–32 (2013).
  • Romagnoli E, Cipriani C, Nofroni I et al. “Trabecular Bone Score” (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone 53(1), 154–159 (2013).
  • Siilin H, Lundgren E, Mallmin H et al. Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden. World J. Surg. 35(6), 1266–1272 (2011).
  • Stein EM, Silva BC, Boutroy S et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J. Bone Miner. Res. 28(5), 1029–1040 (2013).
  • Wood K, Dhital S, Chen H, Sippel RS. What is the utility of distal forearm DXA in primary hyperparathyroidism? Oncologist 17(3), 322–325 (2012).
  • Eller-Vainicher C, Filopanti M, Palmieri S et al. Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur. J. Endocrinol. 169(2), 155–162 (2013).
  • Vu TD, Wang XF, Wang Q et al. New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. Bone 55(1), 57–63 (2013).
  • Walker MD, Dempster DW, McMahon DJ et al. Effect of renal function on skeletal health in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 97(5), 1501–1507 (2012).
  • Stein EM, Dempster DW, Udesky J et al. Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone 48(3), 557–561 (2011).
  • Kerschan-Schindl K, Riss P, Krestan C et al. Bone metabolism in patients with primary hyperparathyroidism before and after surgery. Horm. Metab. Res. 44(6), 476–481 (2012).
  • Hansen S, Hauge EM, Rasmussen L, Jensen JE, Brixen K. Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography. J. Bone Miner. Res. 27(5), 1150–1158 (2012).
  • Sitges-Serra A, Garcia L, Prieto R, Pena MJ, Nogues X, Sancho JJ. Effect of parathyroidectomy for primary hyperparathyroidism on bone mineral density in postmenopausal women. Br. J. Surg. 97(7), 1013–1019 (2010).
  • Dy BM, Grant CS, Wermers RA et al. Changes in bone mineral density after surgical intervention for primary hyperparathyroidism. Surgery 152(6), 1051–1058 (2012).
  • Rolighed L, Vestergaard P, Heickendorff L et al. BMD improvements after operation for primary hyperparathyroidism. Langenbecks Arch. Surg. 398(1), 113–120 (2013).
  • Walker MD, Rubin M, Silverberg SJ. Nontraditional manifestations of primary hyperparathyroidism. J. Clin. Densitom. 16(1), 40–47 (2013).
  • Bai HX, Giefer M, Patel M, Orabi AI, Husain SZ. The association of primary hyperparathyroidism with pancreatitis. J. Clin. Gastroenterol. 46(8), 656–661 (2012).
  • Ebert EC. The parathyroids and the gut. J. Clin. Gastroenterol. 44(7), 479–482 (2010).
  • Pepe J, Badiali D, Biviano I et al. The effect of parathyroidectomy on chronic constipation in patients affected by primary hyperparathyroidism. J. Bone Miner. Metab. (2013).
  • Bhadada SK, Bhansali A, Shah VN, Behera A, Ravikiran M, Santosh R. High prevalence of cholelithiasis in primary hyperparathyroidism: a retrospective analysis of 120 cases. Indian J. Gastroenterol. 30(2), 100–101 (2011).
  • Massironi S, Cavalcoli F, Rossi RE et al. Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. Eur. J. Endocrinol. 168(5), 755–761 (2013).
  • Anderson JL, Vanwoerkom RC, Horne BD et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am. Heart J. 162(2), 331–339 e332 (2011).
  • Hagstrom E, Ingelsson E, Sundstrom J et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur. J. Heart Fail. 12(11), 1186–1192 (2010).
  • Han D, Trooskin S, Wang X. Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J. Endocrinol. Invest. 35(6), 548–552 (2012).
  • Farahnak P, Larfars G, Sten-Linder M, Nilsson IL. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. J. Clin. Endocrinol. Metab. 96(7), 2112–2118 (2011).
  • Tassone F, Procopio M, Gianotti L et al. Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet. Med. 26(10), 968–973 (2009).
  • Yamaguchi T, Kanazawa I, Takaoka S, Sugimoto T. Serum calcium is positively correlated with fasting plasma glucose and insulin resistance, independent of parathyroid hormone, in male patients with type 2 diabetes mellitus. Metabolism 60(9), 1334–1339 (2011).
  • Luboshitzky R, Chertok-Schaham Y, Lavi I, Ishay A. Cardiovascular risk factors in primary hyperparathyroidism. J. Endocrinol. Invest. 32(4), 317–321 (2009).
  • Almqvist EG, Bondeson AG, Bondeson L, Mellstrom D, Svensson J. Factors influencing insulin sensitivity in patients with mild primary hyperparathyroidism before and after parathyroidectomy. Scand. J. Clin. Lab. Invest. 72(2), 92–99 (2012).
  • Bhadada SK, Bhansali A, Shah VN, Rao DS. Changes in serum leptin and adiponectin concentrations and insulin resistance after curative parathyroidectomy in moderate to severe primary hyperparathyroidism. Singapore Med. J. 52(12), 890–893 (2011).
  • Gianotti L, Piovesan A, Croce CG et al. Interplay between serum osteocalcin and insulin sensitivity in primary hyperparathyroidism. Calcif. Tissue Int. 88(3), 231–237 (2011).
  • Rudman A, Pearson ER, Smith D, Srivastava R, Murphy MJ, Leese GP. Insulin resistance before and after parathyroidectomy in patients with primary hyperparathyroidism--a pilot study. Endocr. Res. 35(2), 85–93 (2010).
  • Cheng SP, Doherty GM, Chang YC, Liu CL. Leptin: the link between overweight and primary hyperparathyroidism? Med. Hypotheses 76(1), 94–96 (2011).
  • Pitt SC, Panneerselvan R, Sippel RS, Chen H. Influence of morbid obesity on parathyroidectomy outcomes in primary hyperparathyroidism. Am. J. Surg. 199(3), 410–414, discussion 414-415 (2010).
  • Adam MA, Untch BR, Danko ME et al. Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 95(11), 4917–4924 (2010).
  • Christensen MH, Dankel SN, Nordbo Y et al. Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue. PLoS ONE 6(6), e20481 (2011).
  • Emam AA, Mousa SG, Ahmed KY, Al-Azab AA. Inflammatory biomarkers in patients with asymptomatic primary hyperparathyroidism. Med. Princ. Pract. 21(3), 249–253 (2012).
  • Almqvist EG, Bondeson AG, Bondeson L, Svensson J. Increased markers of inflammation and endothelial dysfunction in patients with mild primary hyperparathyroidism. Scand. J. Clin. Lab. Invest. 71(2), 139–144 (2011).
  • Lumachi F, Zanella S, Cella G, Casonato A, Fallo F. Endothelial activation markers soluble E-selectin and von Willebrand factor in primary hyperparathyroidism. In Vivo 25(2), 279–282 (2011).
  • Carrelli AL, Walker MD, Di Tullio MR et al. Endothelial function in mild primary hyperparathyroidism. Clin. Endocrinol. (Oxf) 78(2), 204–209 (2013).
  • Letizia C, Ferrari P, Cotesta D et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J. Hum. Hypertens. 19(11), 901–906 (2005).
  • Lumachi F, Camozzi V, Luisetto G, Zanella S, Basso SM. Arterial blood pressure, serum calcium and PTH in elderly men with parathyroid tumors and primary hyperparathyroidism. Anticancer Res. 31(11), 3969–3972 (2011).
  • Heyliger A, Tangpricha V, Weber C, Sharma J. Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. Surgery 146(6), 1042–1047 (2009).
  • Broulik PD, Broulikova A, Adamek S et al. Improvement of hypertension after parathyroidectomy of patients suffering from primary hyperparathyroidism. Int. J. Endocrinol. 2011, 309068 (2011).
  • Schiffl H, Lang SM. Hypertension secondary to PHPT: cause or coincidence? Int. J. Endocrinol. 2011, 974647 (2011).
  • Tomaschitz A, Ritz E, Pieske B et al. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc. Res. 94(1), 10–19 (2012).
  • Brunaud L, Germain A, Zarnegar R et al. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery 146(6), 1035–1041 (2009).
  • Maniero C, Fassina A, Seccia TM et al. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J. Hypertens. 30(2), 390–395 (2012).
  • Tomaschitz A, Fahrleitner-Pammer A, Pieske B et al. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. BMC Endocr. Disord. 12, 19 (2013).
  • Osto E, Fallo F, Pelizzo MR et al. Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation 126(9), 1031–1039 (2012).
  • Marini C, Giusti M, Armonino R et al. Reduced coronary flow reserve in patients with primary hyperparathyroidism: a study by G-SPECT myocardial perfusion imaging. Eur. J. Nucl. Med. Mol. Imaging 37(12), 2256–2263 (2010).
  • Pepe J, Curione M, Morelli S et al. Arrhythmias in primary hyperparathyroidism evaluated by exercise test. Eur. J. Clin. Invest. 43(2), 208–214 (2013).
  • Pepe J, Curione M, Morelli S et al. Parathyroidectomy eliminates arrhythmic risk in primary hyperparathyroidism, as evaluated by exercise test. Eur. J. Endocrinol. 169(2), 255–261 (2013).
  • Walker MD, Fleischer J, Rundek T et al. Carotid vascular abnormalities in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94(10), 3849–3856 (2009).
  • Walker MD, Rundek T, Homma S et al. Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism. Eur. J. Endocrinol. 167(2), 277–285 (2012).
  • Schillaci G, Pucci G, Pirro M et al. Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis 218(1), 96–101 (2011).
  • Aktas Yilmaz B, Akyel A, Kan E et al. Cardiac structure and functions in patients with asymptomatic primary hyperparathyroidism. J. Endocrinol. Invest. 36(10), 848–852 (2013).
  • Walker MD, Fleischer JB, Di Tullio MR et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 95(5), 2172–2179 (2010).
  • Kiris A, Erem C, Kiris G et al. The assessment of left ventricular systolic asynchrony in patients with primary hyperparathyroidism. Echocardiography 28(9), 955–960 (2011).
  • Iwata S, Walker MD, Di Tullio MR et al. Aortic valve calcification in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 97(1), 132–137 (2012).
  • Birgander M, Juul-Moller S, Bondeson AG, Bondeson L, Rydberg E. Adrenergic and cardiac dysfunction in primary hyperparathyroidism. Clin. Endocrinol. (Oxf) 76(2), 189–195 (2012).
  • Farahnak P, Ring M, Caidahl K, Farnebo LO, Eriksson MJ, Nilsson IL. Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy. Eur. J. Endocrinol. 163(3), 461–467 (2010).
  • Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 89(11), 5415–5422 (2004).
  • Ambrogini E, Cetani F, Cianferotti L et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J. Clin. Endocrinol. Metab. 92(8), 3114–3121 (2007).
  • Bollerslev J, Jansson S, Mollerup CL et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J. Clin. Endocrinol. Metab. 92(5), 1687–1692 (2007).
  • Walker MD, McMahon DJ, Inabnet WB et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J. Clin. Endocrinol. Metab. 94(6), 1951–1958 (2009).
  • Espiritu RP, Kearns AE, Vickers KS, Grant C, Ryu E, Wermers RA. Depression in primary hyperparathyroidism: prevalence and benefit of surgery. J. Clin. Endocrinol. Metab. 96(11), E1737–E1745 (2011).
  • Babinska D, Barczynski M, Stefaniak T et al. Evaluation of selected cognitive functions before and after surgery for primary hyperparathyroidism. Langenbecks Arch. Surg. 397(5), 825–831 (2012).
  • Weber T, Eberle J, Messelhauser U et al. Parathyroidectomy, elevated depression scores, and suicidal ideation in patients with primary hyperparathyroidism: results of a prospective multicenter study. JAMA Surg. 148(2), 109–115 (2013).
  • Kahal H, Aye M, Rigby AS, Sathyapalan T, England RJ, Atkin SL. The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism. Clin. Endocrinol. (Oxf) 76(2), 196–200 (2012).
  • Pasieka JL, Parsons L, Jones J. The long-term benefit of parathyroidectomy in primary hyperparathyroidism: a 10-year prospective surgical outcome study. Surgery 146(6), 1006–1013 (2009).
  • Perrier ND, Balachandran D, Wefel JS et al. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with “asymptomatic” primary hyperparathyroidism. Surgery 146(6), 1116–1122 (2009).
  • Roman SA, Sosa JA, Pietrzak RH et al. The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Ann. Surg. 253(1), 131–137 (2011).
  • Valcour A, Blocki F, Hawkins DM, Rao SD. Effects of age and serum 25-OH-vitamin D on serum parathyroid hormone levels. J. Clin. Endocrinol. Metab. 97(11), 3989–3995 (2012).
  • Harvey A, Hu M, Gupta M et al. A new, vitamin D-based, multidimensional nomogram for the diagnosis of primary hyperparathyroidism. Endocr. Pract. 18(2), 124–131 (2012).
  • Mazeh H, Sippel RS, Chen H. The role of gender in primary hyperparathyroidism: same disease, different presentation. Ann. Surg. Oncol. 19(9), 2958–2962 (2012).
  • De Lucia F, Minisola S, Romagnoli E et al. Effect of gender and geographic location on the expression of primary hyperparathyroidism. J. Endocrinol. Invest. 36(2), 123–126 (2013).
  • Amstrup AK, Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Effects of smoking on severity of disease in primary hyperparathyroidism. Calcif. Tissue Int. 87(5), 406–413 (2010).
  • Norman J, Goodman A, Politz D. Calcium, parathyroid hormone, and vitamin D in patients with primary hyperparathyroidism: normograms developed from 10,000 cases. Endocr. Pract. 17(3), 384–394 (2011).
  • Ong GS, Walsh JP, Stuckey BG et al. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 97(9), 3138–3145 (2012).
  • Tee MC, Holmes DT, Wiseman SM. Ionized vs serum calcium in the diagnosis and management of primary hyperparathyroidism: which is superior? Am. J. Surg. 205(5), 591–596, discussion 596 (2013).
  • Nordenstrom E, Katzman P, Bergenfelz A. Biochemical diagnosis of primary hyperparathyroidism: analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin. Biochem. 44(10–11), 849–852 (2011).
  • Shinall MC, Dahir KM, Broome JT. Differentiating familial hypocalciuric hypercalcemia from primary hyperparathyroidism. Endocr. Pract. 1–19 (2013).
  • Jayasena CN, Mahmud M, Palazzo F, Donaldson M, Meeran K, Dhillo WS. Utility of the urine calcium-to-creatinine ratio to diagnose primary hyperparathyroidism in asymptomatic hypercalcaemic patients with vitamin D deficiency. Ann. Clin. Biochem. 48(Pt 2), 126–129 (2011).
  • Taha W, Singh N, Flack JM, Abou-Samra AB. Low urine calcium excretion in African American patients with primary hyperparathyroidism. Endocr. Pract. 17(6), 867–872 (2011).
  • Eldeiry LS, Ruan DT, Brown EM, Gaglia JL, Garber JR. Primary hyperparathyroidism and familial hypocalciuric hypercalcemia: relationships and clinical implications. Endocr. Pract. 18(3), 412–417 (2012).
  • Watts NB, Bilezikian JP, Camacho PM et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr. Pract. 16( Suppl. 3), 1–37 (2010).
  • Rubin MR, Bilezikian JP, McMahon DJ et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J. Clin. Endocrinol. Metab. 93(9), 3462–3470 (2008).
  • Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341(17), 1249–1255 (1999).
  • Yu N, Leese GP, Smith D, Donnan PT. The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study. QJM 104(6), 513–521 (2011).
  • Lundgren E, Lind L, Palmer M, Jakobsson S, Ljunghall S, Rastad J. Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery 130(6), 978–985 (2001).
  • Yu N, Leese GP, Donnan PT. What predicts adverse outcomes in untreated primary hyperparathyroidism? The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin. Endocrinol. (Oxf) 79(1), 27–34 (2013).
  • Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism. Arq. Bras. Endocrinol. Metabol. 54(2), 106–109 (2010).
  • Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J. Clin. Densitom. 16(1), 33–39 (2013).
  • Campenni A, Ruggeri RM, Sindoni A et al. Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism. J. Bone Miner. Metab. 30(3), 367–372 (2012).
  • Cusano NE, Maalouf NM, Wang PY et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J. Clin. Endocrinol. Metab. 98(7), 2734–2741 (2013).
  • Marques TF, Vasconcelos R, Diniz E, Rego D, Griz L, Bandeira F. Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq. Bras. Endocrinol. Metabol. 55(5), 314–317 (2011).
  • Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J. Osteoporos. 2012, 128352 (2012).
  • Rejnmark L, Amstrup AK, Mollerup CL, Heickendorff L, Mosekilde L. Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study. J. Clin. Endocrinol. Metab. 98(1), 87–96 (2013).
  • Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 92(8), 3001–3005 (2007).
  • Koumakis E, Souberbielle JC, Sarfati E et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 98(8), 3213–3220 (2013).
  • Tordjman KM, Yaron M, Izkhakov E et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur. J. Endocrinol. 162(5), 925–933 (2010).
  • Cakir I, Unluhizarci K, Tanriverdi F, Elbuken G, Karaca Z, Kelestimur F. Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine 42(2), 419–422 (2012).
  • Bollerslev J, Marcocci C, Sosa M, Nordenstrom J, Bouillon R, Mosekilde L. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur. J. Endocrinol. 165(6), 851–864 (2011).
  • Saponaro F, Faggiano A, Grimaldi F et al. Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clin. Endocrinol. (Oxf) 79(1), 20–26 (2013).
  • Marcocci C, Chanson P, Shoback D et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94(8), 2766–2772 (2009).
  • Peacock M, Bolognese MA, Borofsky M et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J. Clin. Endocrinol. Metab. 94(12), 4860–4867 (2009).
  • Peacock M, Bilezikian JP, Bolognese MA et al. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J. Clin. Endocrinol. Metab. 96(1), E9–E18 (2011).
  • Cetani F, Saponaro F, Banti C et al. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. J. Endocrinol. Invest. 35(7), 655–660 (2012).
  • Luque-Fernandez I, Garcia-Martin A, Luque-Pazos A. Experience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment. Ther. Adv. Endocrinol. Metab. 4(3), 77–81 (2013).
  • Norman J, Lopez J, Politz D. Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use. Ann. Surg. Oncol. 19(5), 1466–1471 (2012).
  • Faggiano A, Di Somma C, Ramundo V et al. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine 39(3), 283–287 (2011).
  • Filopanti M, Verga U, Ermetici F et al. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Eur. J. Endocrinol. 167(2), 157–164 (2012).
  • Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. Int. J. Endocrinol. 2010, 906163 (2010).
  • Keutgen XM, Buitrago D, Filicori F et al. Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database. Ann. Surg. 255(5), 981–985 (2012).
  • Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 373–381 (2009).
  • Carnevale V, Del Fiacco R, Romagnoli E et al. Effects of strontium ranelate administration on calcium metabolism in female patients with postmenopausal osteoporosis and primary hyperparathyroidism. Calcif. Tissue Int. 92(1), 15–22 (2013).
  • Khan AA, Bilezikian JP, Kung AW et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89(7), 3319–3325 (2004).
  • Khan AA, Bilezikian JP, Kung A, Dubois SJ, Standish TI, Syed ZA. Alendronate therapy in men with primary hyperparathyroidism. Endocr. Pract. 15(7), 705–713 (2009).
  • Rossini M, Viapiana O, Kalpakcioglu B et al. Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism. Calcif. Tissue Int. 89(1), 21–28 (2011).
  • Tournis S, Fakidari E, Dontas I et al. Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism. J. Bone Miner. Metab. (2013) ( Epub ahead of print).
  • Sankaran S, Gamble G, Bolland M, Reid IR, Grey A. Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J. Clin. Endocrinol. Metab. 95(4), 1653–1662 (2010).
  • Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361(8), 756–765 (2009).
  • Szymczak J, Bohdanowicz-Pawlak A. Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate. Horm. Metab. Res. 45(10), 759–764 (2013).
  • Saliba W, Lavi I, Rennert HS, Rennert G. Vitamin D status in primary hyperparathyroidism. Eur. J. Intern. Med. 23(1), 88–92 (2012).
  • Tassone F, Gianotti L, Baffoni C et al. Vitamin D status in primary hyperparathyroidism: a Southern European perspective. Clin. Endocrinol. (Oxf) (2013).
  • Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. J. Bone Miner. Res. 22( Suppl. 2), V100–V104 (2007).
  • Wang X, Shapses SA, Wei S, Sukumar D, Ghosh J. Vitamin D Binding Protein Levels in Female Patients with Primary Hyperparathyroidism. Endocr. Pract. 1–15 (2013).
  • Untch BR, Barfield ME, Dar M, Dixit D, Leight GS Jr, Olson JA Jr. Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 142(6), 1022–1026 (2007).
  • Jayasena CN, Modi M, Palazzo F et al. Associations of serum 25-hydroxyvitamin D with circulating PTH, phosphate and calcium in patients with primary hyperparathyroidism. Clin. Endocrinol. (Oxf) 78(6), 838–843 (2013).
  • Eastell R, Arnold A, Brandi ML et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 340–350 (2009).
  • Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 351–365 (2009).
  • Isidro ML, Ruano B. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 36(2), 305–310 (2009).
  • Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J. Clin. Endocrinol. Metab. 90(4), 2122–2126 (2005).
  • Tucci JR. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur. J. Endocrinol. 161(1), 189–193 (2009).
  • Wagner D, Xia Y, Hou R. Safety of vitamin d replacement in patients with primary hyperparathyroidism and concomitant vitamin d deficiency. Endocr. Pract. 19(3), 420–425 (2013).
  • Rao RR, Randeva HS, Sankaranarayanan S et al. Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism. Endocr. Connect. 1(1), 13–21 (2012).
  • Bilezikian JP, Khan AA, Potts JT, Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 335–339 (2009).
  • Khan AA, Bilezikian JP, Potts JT Jr. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J. Clin. Endocrinol. Metab. 94(2), 333–334 (2009).
  • Dowthwaite SA, Young JE, Pasternak JD, Yoo J. Surgical management of primary hyperparathyroidism. J. Clin. Densitom. 16(1), 48–53 (2013).
  • Caldarella C, Treglia G, Isgro MA, Giordano A. Diagnostic performance of positron emission tomography using (1)(1)C-methionine in patients with suspected parathyroid adenoma: a meta-analysis. Endocrine 43(1), 78–83 (2013).
  • Johnson NA, Tublin ME, Ogilvie JB. Parathyroid imaging: technique and role in the preoperative evaluation of primary hyperparathyroidism. AJR Am. J. Roentgenol. 188(6), 1706–1715 (2007).
  • Reidel MA, Schilling T, Graf S et al. Localization of hyperfunctioning parathyroid glands by selective venous sampling in reoperation for primary or secondary hyperparathyroidism. Surgery 140(6), 907–913, discussion 913 (2006).
  • Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 366–372 (2009).
  • Coakley AJ, Kettle AG, Wells CP, O’Doherty MJ, Collins RE. 99Tcm sestamibi--a new agent for parathyroid imaging. Nucl. Med. Commun. 10(11), 791–794 (1989).
  • Augustine MM, Bravo PE, Zeiger MA. Surgical treatment of primary hyperparathyroidism. Endocr. Pract. 17( Suppl. 1), 75–82 (2011).
  • Kim YI, Jung YH, Hwang KT, Lee HY. Efficacy of (9)(9)mTc-sestamibi SPECT/CT for minimally invasive parathyroidectomy: comparative study with (9)(9)mTc-sestamibi scintigraphy, SPECT, US and CT. Ann. Nucl. Med. 26(10), 804–810 (2012).
  • Lew JI, Solorzano CC. Surgical management of primary hyperparathyroidism: state of the art. Surg. Clin. North Am. 89(5), 1205–1225 (2009).
  • Untch BR, Adam MA, Scheri RP et al. Surgeon-performed ultrasound is superior to 99Tc-sestamibi scanning to localize parathyroid adenomas in patients with primary hyperparathyroidism: results in 516 patients over 10 years. J. Am. Coll. Surg. 212(4), 522–529; discussion 529–531 (2011).
  • Haber RS, Kim CK, Inabnet WB. Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m)technetium sestamibi scintigraphy. Clin. Endocrinol. (Oxf) 57(2), 241–249 (2002).
  • Hunter GJ, Schellingerhout D, Vu TH, Perrier ND, Hamberg LM. Accuracy of four-dimensional CT for the localization of abnormal parathyroid glands in patients with primary hyperparathyroidism. Radiology 264(3), 789–795 (2012).
  • Steven AE. Historical perspectives on parathyroid surgery. Clin. Rev. Bone Miner. Metab. 5, 75–80 (2007).
  • Bilezikian JP. Primary hyperparathyroidism. Endocr. Pract. 18(5), 781–790 (2012).
  • Carneiro DM, Solorzano CC, Nader MC, Ramirez M, Irvin GL, 3rd. Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery 134(6), 973–979, discussion 979–981 (2003).
  • McGill J, Sturgeon C, Kaplan SP, Chiu B, Kaplan EL, Angelos P. How does the operative strategy for primary hyperparathyroidism impact the findings and cure rate? A comparison of 800 parathyroidectomies. J. Am. Coll. Surg. 207(2), 246–249 (2008).
  • Rio PD, Vicente D, Maestroni U et al. A comparison of minimally invasive video-assisted parathyroidectomy and traditional parathyroidectomy for parathyroid adenoma. J. Cancer 4(6), 458–463 (2013).
  • Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann. Surg. 253(3), 585–591 (2011).
  • Schneider DF, Mazeh H, Sippel RS, Chen H. Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1000 cases. Surgery 152(6), 1008–1015 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.